Adaptogenics Health Corp. (CSE: ADPT) has appointed Antoun Nabhan, J.D., as President, effective October 1, 2026, the company announced on October 13, 2026. Nabhan brings nearly two decades of healthcare investment and corporate finance experience, having led or advised on more than $2 billion in buy-side healthcare transactions. The appointment signals Adaptogenics' intent to build a proprietary pipeline of peptide and small molecule therapeutics alongside its existing nutraceutical business, and investors may be watching for asset acquisitions and licensing activity under Nabhan's leadership.

Key Points

  • Adaptogenics Health Corp. (CSE: ADPT) is a Canadian-based nutraceutical and emerging therapeutics company
  • Antoun Nabhan, J.D., appointed President effective October 1, 2026
  • Nabhan has been involved in more than $2 billion in healthcare transactions and led two Nasdaq IPO processes
  • Investors may be watching for updates on peptide and small molecule pipeline development and strategic partnership activity

Nabhan's Healthcare Transaction and Executive Track Record

Nabhan previously served as Senior Vice President at Oaktree Capital Management and currently manages publicly traded healthcare equities at Sagamore Bioventures. His operating roles have included Chief Financial Officer of Establishment Labs and Vice President of Corporate Development at Raptor Pharmaceuticals, Pear Therapeutics, and Capnia, now Soleno Therapeutics. He also held transactional executive roles at Onyx Pharmaceuticals before its acquisition by Amgen, and at Raptor Pharmaceuticals before its acquisition by Horizon Pharma. He co-founded three pharmaceutical development companies, two of which — Convivia and Incellico — have been acquired.

Assets and IPO Processes Linked to Nabhan's Career

The company's announcement states that Nabhan has led or advised on transactions involving multiple assets that subsequently received regulatory approval, including Kyprolis, Stivarga, Quinsair, and Somryst. He also led two Nasdaq initial public offering processes across his roles at Establishment Labs and Soleno Therapeutics, formerly Capnia, Inc. Nabhan holds a J.D. from Harvard Law School and an A.B. from the University of Chicago, where he graduated Phi Beta Kappa, according to the release.

Nabhan's Mandate at Adaptogenics and Strategic Direction

As President, Nabhan will lead identification, evaluation, and negotiation of asset acquisitions, licensing partnerships, and strategic collaborations. The release states he will work alongside Chief Executive Officer Dr. J. David Warren to connect scientific evaluation with transaction structure and capital planning as Adaptogenics pursues proprietary peptide and small molecule opportunities focused on metabolic health, muscle preservation, and inflammation. The company also stated it is evaluating complementary GLP-1 companion product opportunities alongside its existing nutraceutical operations. The immediate share price impact was not clear from available public information.